Total cohort n=25 | Responders n=12 | Non-responders n=11 | P value | |
Demographics | ||||
Age (years, mean±SD) | 73.4±10.0 | 68.1±14.4 | 76.0±7.4 | 0.19 |
Male (n,%) | 23 (92.0%) | 12 (100.0%) | 9 (81.8%) | 0.42 |
Device | ||||
CRT-D (n,%) | 18 (72.0) | 8 (66.7) | 9 (81.8) | 0.73 |
Upgrade (n,%) | 9 (36.0) | 2 (16.7) | 7 (63.6) | 0.06 |
Aetiology | ||||
Ischaemic (n,%) | 16 (64.0) | 6 (50.0) | 8 (72.7) | 0.49 |
Non-ischaemic (n,%) | 9 (36.0) | 6 (50.0) | 3 (27.3) | |
Comorbidities | ||||
Diabetes mellitus (n,%) | 6 (24.0) | 2 (16.7) | 4 (36.4) | 0.55 |
CKD (n,%) | 13 (52.0) | 7 (58.3) | 6 (54.5) | 1.00 |
NYHA (n,%) | ||||
II | 10 (43.5) | 5 (41.7) | 5 (45.5) | 0.52 |
III | 12 (52.2) | 7 (58.3) | 5 (45.5) | |
IV | 1 (4.3) | 0 (0.0) | 1 (9.1) | |
ECG | ||||
AF (n,%) | 9 (36.0) | 4 (33.3) | 4 (36.4) | 1.00 |
LBBB (n,%) | 17 (68.0) | 9 (75.0) | 6 (54.5) | 0.56 |
QRS (ms, median, range) | 162(120–212) | 168 (138–212) | 160 (138–194) | 0.60 |
6MWT (M, mean±SD) | 252.6±132.0 | 291.9±133.3 | 215.3±147.4 | 0.29 |
QOL score (median, range) | 48.0 (8.0–85.0) | 55.5 (9.0–85.0) | 29.0 (8.0–68.0) | 0.11 |
Laboratory tests | ||||
eGFR (ml/min/1.73 m2, median, range) | 52.0 (25.0–130.0) | 52.5 (25.0–130.0) | 52.0 (26.0–79.0) | 0.61 |
NT-pro-BNP (pmol/L, median, range) | 267.0 (75.0–4138.0) | 237.0 (75.0–4138.0) | 273.0 (133.0–547.0) | 0.33 |
Medications | ||||
ACEi/ARB (n,%) | 25 (100.0) | 12 (100.0) | 11 (100.0) | 1.00 |
BB (n,%) | 21 (84.0) | 10 (83.3) | 10 (90.9) | 0.62 |
MRA (n,%) | 14 (56.0) | 7 (58.3) | 5 (45.5) | 0.38 |
Echocardiography* | ||||
LVESV (mL, median, range) | 125.8 (62.9–268.7) | 136.7 (80.7–268.7) | 110.9 (62.9–169.4) | 0.29 |
LVESV_BSA(mL, median, range) | 58.9 (38.7–128.0) | 66.1 (42.7–128.0) | 59.1 (38.7–85.8) | 0.35 |
LVEF (%, median, range) | 25.6 (9.7–35.4) | 24.4 (10.0–34.4) | 28.6 (9.7–35.4) | 0.40 |
Body composition | ||||
BMI (kg/m2, median, range) | 28.7 (22.4–41.9) | 29.3 (22.4–37.3) | 27.8 (23.9–40.8) | 0.85 |
FM (kg, median, range) | 31.4 (18.1–61.2) | 31.3 (19.3–56.4) | 29.7 (18.1–58.7) | 0.81 |
Relative FM (median, range) | 0.38 (0.23–0.54) | 0.35 (0.28–0.50) | 0.42 (0.23–0.54) | 0.29 |
Lean mass (kg, median, range) | 52.3 (30.9–73.3) | 52.6 (40.3–73.3) | 50.5 (30.9–62.5) | 0.48 |
Waist (cm, median, range) | 98.2 (84.6–131.0) | 97.5 (84.6–120.8) | 98.2 (85.0–114.5) | 0.79 |
*Based on available data
ACEi, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, ACE receptor antagonist; BMI, body mass index; BNP, brain natriuretic peptide; BSA, body surface area; CKD, chronic kidney disease; CRT, cardiac resynchronisation therapy; eGFR, estimated glomerular filtration rate; FM, fat mass; LBBB, Left bundle branch block; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; 6MWT, 6 min walk test; NT-pro-BNP, N-terminal probrain natriuretic peptide; NYHA, New York Heart Failure Assessment; QOL, quality of life; QRS, QRS width on ECG.